...read the wave

2006 Nano Biz...in depth... im detail


Capsulution contributes to worldwide nanotech network

Berlin based company becomes member of the European Nanotechnology Trade
Alliance (ENTA)

Berlin, May 15th, 2006 – In April the Capsulution NanoScience AG, a Berlin based nanotechnology company that is specialised in the development of intelligent "packaging" systems for active substances has become a member of the European Nanotechnology Trade Alliance (ENTA). As a leading organization and opinion leader in nanotechnology, ENTA aims at mentoring, networking and contacting among nanotech providers such as Capsulution and with potential customers and investors. Members of ENTA already include companies such as Procter & Gamble, Unilever or Shell Technology Ventures and many others.

For Capsulution, it is very important to join forces with other players in the field. We need to create larger networking between different nanotech providers on one hand, and with different customer industries on the other hand." says Alexander Herrmann, CFO at Capsulution. "In addition, we have to clarify "What is nanotechnology about?" to whom, who is not familiar with this new approach. Finally, our membership with ENTA represents a quality feature differentiating Capsulution from other suppliers."

Together with other leading nanotech companies, Capsulution's contribution is dedicated to increasing the awareness of consumers, industrial clients and investors with respect to Nanotechnology and its social and economic impact for the society. Del Stark, CEO of ENTA: "We are very proud to have Capsulution as a new member as this company is a leader in the development of new life science products for the pharmaceutical market."

About ENTA:
The European Nanotechnology Trade Alliance (ENTA) represents the interests of its members across Europe ENTA offers an integrated programme aimed at promoting the benefits of nanotechnology and mitigating regulatory and reputational risk for the whole industry and supporting all actions that ensure new nanotechnologies are developed in a safe and responsible manner.

In addition to the above, ENTA represents the interests of nanotechnology businesses across Europe and acts to bridge the gap between industry, governments, science, and importantly, the public in promoting the benefits of nanotechnology.

ENTA works closely with the media and government bodies to express the nanotechnology industry's views and needs, on for example, legislation, standards, standard operating procedures, and public support.

Contact person

Del Stark

Capsulution Nanoscience AG
Herr Dipl.-Kfm. Alexander Herrmann
E-Mail: alexander.herrmann@capsulution.com

Telefon: +49 (0)30-63 92 36 00
Fax: +49 (0)30-63 92 36 01

About Capsulution NanoScience AG:
Capsulution NanoScience AG is a leading nanotechnolopy company focusing on the development of tailor-made drug delivery systems and other innovative life science products based on nano-sized capsules. The company applies its worldwide-patented so-called LBL-Technology®. Based on their minute size, their functionality and their highly reproducible production process the capsules can be used for a multitude of different applications.

Accordingly, the precisely sized capsules can be made to function in a manner to suit the intended application, and can be given the appropriate biochemical, electrical, optical and magnetic properties as required by the customer. In order to meet customers needs for complete product solutions Capsulution has recently designated a Japanese licensee as the preferred developer, manufacturer and distributor for automated LBL-units. Only six month after the signing of the licence agreement, EBARA has started operation of the first prototype plant (LBL-Unit®) for the manufacture of Capsulution's LBL capsules. In 2005, renowned growth consultants Frost & Sullivan have awarded the year's "Product Differentiation Innovation Award" in the global nanobiotechnology market to Capsulution NanoScience AG, Berlin. The company has received the award for the innovative and diverse use of their proprietary nanobiotechnology product platform, which can be implemented in various life sciences applications.

This story has been adapted from a news release -
Diese Meldung basiert auf einer Pressemitteilung -
Deze tekst is gebaseerd op een nieuwsbericht -


who is reading
the wave ?

missed some news ?
click on archive photo


or how about joining us


or contacting us ?


about us


our mission